Novel rare variants in FGFR1 and clinical characteristics analysis in a series of congenital hypogonadotropic hypogonadism patients
- PMID: 33548149
- DOI: 10.1111/cen.14436
Novel rare variants in FGFR1 and clinical characteristics analysis in a series of congenital hypogonadotropic hypogonadism patients
Abstract
Objective: We aimed to analyse FGFR1 rare variants in a series of Chinese congenital hypogonadotropic hypogonadism (CHH) patients. In addition, we intended to understand the clinical characteristics and the response to treatment of CHH patients with FGFR1 rare variants.
Patients and methods: A total of 357 CHH patients were recruited at Peking Union Medical College Hospital. We used Sanger sequencing to analyse FGFR1 gene. In silico analysis was carried out to study the pathogenicity of novel missense variants. The clinical, endocrinological and therapeutic effects from patients carrying FGFR1 rare variants were analysed retrospectively.
Results: Thimissense mutations.rty patients in this series were found to harbour 29 FGFR1 rare variants, with 8 recurrent and 21 novel variants. After comprehensive analysis, 18 out of 21 novel variants were classified as likely pathogenic (LP) ones. These variants are widely spread throughout the FGFR1 gene and almost all FGFR1 functional domains, which exhibited no hot spot. Cryptorchidism, cleft palate and dental abnormality incidence in this CHH series that possessed FGFR1 LP variants were approximately 38.5%, 7.6% and 3.8%, respectively. Among patients who accepted the fertility-promoting treatment, 8 out of 10 patients succeeded in spermatogenesis.
Conclusions: Eighteen novel LP variants were found to expand the spectrum of FGFR1 rare variants. In CHH patients possessing FGFR1 variants, we found that the rate of spermatogenesis was high following fertility-promoting therapy and the existence of cryptorchidism may represent the underlying factors which affect spermatogenesis.
Keywords: FGFR1; Kallmann syndrome; congenital hypogonadotropic hypogonadism; rare variants.
© 2021 John Wiley & Sons Ltd.
Similar articles
-
Clinical manifestations and spermatogenesis outcomes in Chinese patients with congenital hypogonadotropic hypogonadism caused by inherited or de novo FGFR1 mutations.Asian J Androl. 2024 Jul 1;26(4):426-432. doi: 10.4103/aja202366. Epub 2024 Jan 9. Asian J Androl. 2024. PMID: 38227553 Free PMC article.
-
Expanding the mutational spectrum of monogenic hypogonadotropic hypogonadism: novel mutations in ANOS1 and FGFR1 genes.Reprod Biol Endocrinol. 2020 Jan 29;18(1):8. doi: 10.1186/s12958-020-0568-6. Reprod Biol Endocrinol. 2020. PMID: 31996231 Free PMC article.
-
A Novel FGFR1 Missense Mutation in a Portuguese Family with Congenital Hypogonadotropic Hypogonadism.Int J Mol Sci. 2022 Apr 17;23(8):4423. doi: 10.3390/ijms23084423. Int J Mol Sci. 2022. PMID: 35457241 Free PMC article.
-
Clinical presentation of congenital hypogonadotropic hypogonadism in males with delayed puberty according to genetic etiology: a systematic review and meta-analysis after reclassification of gene variants.Hum Reprod. 2025 May 1;40(5):904-918. doi: 10.1093/humrep/deaf041. Hum Reprod. 2025. PMID: 40101754
-
Congenital hypogonadotropic hypogonadism in females: clinical spectrum, evaluation and genetics.Ann Endocrinol (Paris). 2010 May;71(3):158-62. doi: 10.1016/j.ando.2010.02.024. Epub 2010 Apr 3. Ann Endocrinol (Paris). 2010. PMID: 20363464 Review.
Cited by
-
Classification of CHD7 Rare Variants in Chinese Congenital Hypogonadotropic Hypogonadism Patients and Analysis of Their Clinical Characteristics.Front Genet. 2022 Jan 3;12:770680. doi: 10.3389/fgene.2021.770680. eCollection 2021. Front Genet. 2022. PMID: 35047002 Free PMC article.
-
Effect of pubertal induction with combined gonadotropin therapy on testes development and spermatogenesis in males with gonadotropin deficiency: a cohort study.Hum Reprod Open. 2025 May 13;2025(2):hoaf026. doi: 10.1093/hropen/hoaf026. eCollection 2025. Hum Reprod Open. 2025. PMID: 40463510 Free PMC article.
-
Clinical manifestations and spermatogenesis outcomes in Chinese patients with congenital hypogonadotropic hypogonadism caused by inherited or de novo FGFR1 mutations.Asian J Androl. 2024 Jul 1;26(4):426-432. doi: 10.4103/aja202366. Epub 2024 Jan 9. Asian J Androl. 2024. PMID: 38227553 Free PMC article.
-
Seminal Plasma Lipidomics Profiling to Identify Signatures of Kallmann Syndrome.Front Endocrinol (Lausanne). 2021 Jul 29;12:692690. doi: 10.3389/fendo.2021.692690. eCollection 2021. Front Endocrinol (Lausanne). 2021. PMID: 34393999 Free PMC article.
-
Seminal plasma metabolomics signatures of normosmic congenital hypogonadotropic hypogonadism.Heliyon. 2023 Mar 23;9(4):e14779. doi: 10.1016/j.heliyon.2023.e14779. eCollection 2023 Apr. Heliyon. 2023. PMID: 37025907 Free PMC article.
References
REFERENCES
-
- Young J, Xu C, Papadakis GE, et al. Clinical management of congenital hypogonadotropic hypogonadism. Endocr Rev. 2019;40:669-710.
-
- Lima Amato LG, Latronico AC, Gontijo Silveira LF. Molecular and genetic aspects of congenital isolated hypogonadotropic hypogonadism. Endocrinol Metab Clin North Am. 2017;46:283-303.
-
- Dodé C, Levilliers J, Dupont J-M, et al. Loss-of-function mutations in FGFR1 cause autosomal dominant Kallmann syndrome. Nat Genet. 2003;33:463-465.
-
- Wang D, Niu Y, Tan J, et al. Combined in-vitro and in-silico analyses of FGFR1 variants: genotype-phenotype study in idiopathic hypogonadotropic hypogonadism [published online ahead of print, 2020 Jul 14]. Clin Genet. 2020;98(4):341-352. https://doi.org/10.1111/cge.13814
-
- Xu N, Qin Y, Reindollar RH, Tho SP, McDonough PG, Layman LC. A mutation in the fibroblast growth factor receptor 1 gene causes fully penetrant normosmic isolated hypogonadotropic hypogonadism. J Clin Endocrinol Metab. 2007;92:1155-1158.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous